Biden Admin Pays Ellume $231M To Build COVID-19 US Test Plant
Executive Summary
The government seems to be betting the company’s over-the-counter at-home antigen diagnostic test will be a game changer in stopping the spread of the coronavirus.
You may also be interested in...
Top Republican Senators Criticize Biden Administration For Lack Of COVID-19 Tests
The top GOPers on the Senate health committee want to know what the administration has done with more than $80bn allocated by Congress to ramp up production of COVID-19 tests.
Developer Of First US OTC COVID-19 Antigen Test Plans 'Digital Diagnostics For Multitude Of Infectious Diseases'
The developer of the OTC at-home antigen test — the first of its kind to get an emergency use authorization from the FDA – received more than $200m from the US government to manufacture in the US. So what’s next for Ellume? In this Q&A, the Australian company’s CEO, Sean Parson, explains.
Ellume CEO Ponders Future Of Company’s Rapid COVID-19 Antigen Test
The developer of the at-home over-the-counter antigen test — the first of its kind to get an emergency use authorization from the FDA – received more than $200m from the government to manufacture in the US. So what’s next for Ellume? In this Medtech Insight case study Q&A, the Australian company’s CEO, Sean Parson, explains.